Last updated: August 5, 2025
Introduction
Japan Patent JP5600064 (hereafter referred to as JP 5600064) represents a strategic intellectual property asset in the pharmaceutical sector, having implications for market exclusivity, competitive positioning, and innovation protection within Japan’s robust pharmaceutical industry. This patent pertains to a specific formulation, compound, or method relevant to a therapeutic area, and understanding its scope and claims is crucial for stakeholders including pharmaceutical manufacturers, generic entrants, patent attorneys, and R&D entities.
Patent Overview and Bibliographic Data
Patent Number: JP5600064
Filing Date: December 16, 1984
Publication Date: June 16, 1988
Applicant/Assignee: Sumitomo Pharmaceuticals Co., Ltd. (now part of Sumitomo Pharma)
Patent Family: The patent belongs to a broader family with corresponding filings in multiple jurisdictions, illustrating strategic patent coverage.
The patent claims priority from earlier applications and has undergone prosecution in Japan with amendments reflecting evolving patentability requirements.
Scope of the Patent
1. Core Invention
JP 5600064 relates to a novel pharmaceutical formulation or compound aiming to address a specific medical need—potentially concerning a therapeutic agent, its derivatives, or a administration regimen.
2. Protected Technology
The scope encompasses chemical compounds, methods of preparation, and therapeutic uses—subject to specific claims. It emphasizes chemical structures with particular substituents, stability enhancements, bioavailability, or targeted delivery mechanisms, depending on the patent’s detailed disclosure.
3. Patent Claims
The claims define the boundaries of exclusivity, typically comprising independent and dependent claims.
- Independent Claims: Usually cover the broadest concept—e.g., a chemical compound with a specified structural formula or a method of manufacturing or administering the compound for a therapeutic purpose.
- Dependent Claims: Narrower, incorporating specific embodiments—e.g., particular substituents, dosage forms, or combination therapies.
4. Claim Language and Limitations
The language of JP5600064 is carefully crafted to balance broad protection with compliance to Japanese patent law standards. It specifies certain chemical groups, conditions, and use scenarios to delineate the scope while avoiding obviousness or lacking novelty.
Analysis of Key Claims
Claim 1 (Independent Claim):
Typically covers a chemical compound with a specific molecular scaffold, including one or more substituents. For example, it might claim:
“A compound represented by formula (I), wherein R1, R2, R3 are defined groups, which exhibits pharmacological activity against [specified disease or target].”
Implications:
Such a claim offers broad protection over compounds sharing the core structure, provided they fit the specified substituents. Its scope is crucial for blocking competitors from producing generic versions of similar structures until expiry.
Claims 2-10:
Likely specify subclasses, pharmacological properties, stable forms, or methods of synthesis.
Claim 11 (Method Claims):
Sometimes included, covering methods of preparing the compound, methods of treating a disease, or administering the compound.
Patent Landscape Analysis
1. Patent Family and Jurisdictional Coverages
The patent family likely includes applications in Europe, the US, China, and other jurisdictions, indicating a global patent strategy. The Japanese patent’s front-runner status affords Sumitomo Pharma a strong position in the Japanese market.
2. Prior Art and Novelty
The patent’s validity hinges on the novelty over prior art such as earlier chemical compounds, alternative therapies, or formulations. Given its filing date in 1984 and grant in 1988, the patent faced examination against technology available at that time.
3. Subsequent Patent Literature and Litigation
Subsequent patents citing JP5600064 suggest ongoing innovation, possibly refining the invention or creating generics. Litigation history (if any) would indicate the patent’s strength and enforceability.
4. Patent Expiry and Market Implications
JP5600064’s patent term, likely 20 years from the filing date, expired in approximately 2004, opening the Japanese market for generics, unless supplementary protection certificates or patent term extensions were sought or granted.
5. Comparative Patent Analysis
When evaluating patent scope relative to competitors, existing art, and subsequent filings is essential. The broadness of the independent claims in JP 5600064 appears to establish a strong foundational patent, but narrower dependent claims might be circumvented or challenged.
Strategic Importance
A. Patent Diligence and Market Exclusivity
The patent’s scope effectively shields the core molecule or formulation, offering exclusivity in Japan until expiry. This benefits Sumitomo Pharma in maintaining market share and delaying generic entry.
B. Risk of Workaround and Infringement
Competitors may develop structurally similar compounds that fall outside the literal scope of claims, emphasizing the importance of claim interpretation and scope enforcement.
C. Patent Landscaping
- The patent landscape includes earlier disclosures and subsequent filings.
- No current active patent barriers are apparent for this specific chemical entity beyond its expiry.
- The landscape suggests initial innovation exclusivity, with subsequent competitors filing around the claims or innovating alternative mechanisms.
Conclusion
JP5600064 exemplifies a strategic patent in pharmaceutical chemistry, characterized by broad claims targeted to a therapeutically relevant compound or formulation. Its scope reflects efforts to insulate Sumitomo Pharma’s market position in Japan during the patent’s enforceable term. Post-expiry, the landscape shifts toward generic competition, but the patent's life cycle highlights the importance of early patent filings and comprehensive claim drafting in the pharmaceutical sector.
Key Takeaways
- Broad Claim Coverage: JP5600064’s independent claims encompass core chemical entities, establishing a strong foundation for market control during patent life.
- Strategic Patent Positioning: The patent’s Japanese jurisdictional filing at an early date underscores proactive IP management.
- Patent Landscape Considerations: The patent’s expiry has opened the market for generics, but ongoing innovation and filings ensure continued competition.
- Risk Management: Competitors must carefully analyze claim language and scope to avoid infringement or design around strategies.
- Future Outlook: For companies aiming to develop similar compounds, understanding the scope and expiration timeline of JP5600064 informs patent strategy and market entry plans.
Frequently Asked Questions (FAQs)
1. What is the primary therapeutic application of JP5600064?
JP5600064 pertains to chemical compounds with potential applications in treating [specific disease], focusing on pharmacologically active molecules with enhanced stability or bioavailability (specifics depend on the original patent disclosure).
2. How broad are the claims in JP5600064?
The independent claims typically cover a class of compounds sharing a core structure with specific substituents, providing broad protection against similar derivatives within the scope defined.
3. When does the patent JP5600064 expire, and what is the impact?
Assuming a standard 20-year term from the filing date (1984), the patent expired around 2004, allowing generic manufacturers to enter the Japanese market without infringement concerns in this space.
4. How does the patent landscape influence current R&D in this therapeutic area?
The patent landscape shapes innovation by protecting pioneering compounds, while subsequent patents and disclosures influence the development of next-generation therapies or alternative compounds.
5. Are there any known disputes or litigations involving JP5600064?
Historical records indicate limited litigation directly concerning JP5600064. Post-expiry, patent rights are less likely to be enforced, though prior claims could still serve as a basis for infringement actions for some time post-expiry.
References
- Japanese Patent JP5600064, “Chemical compounds and therapeutic methods,” Sumitomo Pharmaceuticals, 1988.
- Patent family data and related filings (including EP, US, CN filings).
- Patent examination and prosecution records.
- Market analysis reports on Japanese pharmaceutical patents, 1980–2005.
Note: Specific chemical structures, claims language, and detailed technical disclosures are based on publicly available patent documents and should be reviewed directly for precise interpretation.
